Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors

Data will become available on the safety, antitumoral immune response and DC migration in the organism in patients with advance renal cell carcinoma and melanoma from this trial using cellular immunotherapy with dendritic cells loaded with tumor antigens.

This study is not yet open for participant recruitment.
ClinicalTrials.gov Identifier: NCT00610389

Purpose
Background: cellular immunotherapy with dendritic cells (DC) loaded with tumor antigens has shown clinical activity, although in a small number of patients. Therefore, it is mandatory to improve the results of this strategy and to closely monitor immunologic response and cell migration in order to improve our understanding of mechanisms of action and to settle future fields of development.

Objectives
Primary: to confirm clinical activity of this strategy, determining tumor response (RECIST criteria).
Secondary: to determine:
(1) safety;
(2) antitumoral immune response and
(3) DC migration in the organism

Methodology
Phase II trial in patients with advanced renal cell carcinoma and melanoma. We will perform repeated immunizations with DC loaded with the patient´s tumor.

• cell type
• dendritic cell,
• tumor cell

• organism type
• Homo sapiens

created over 16 years ago (19 March 2009)    last modified over 12 years ago (1 October 2012)   [ RDF ]   [ RelFinder ]